Fed’s Powell opens door to potential rate cuts at Jackson Hole
AMSTERDAM—Christian Klemt, the Chief Financial Officer of uniQure N.V. (NASDAQ:QURE), recently sold 10,438 ordinary shares of the company, according to a regulatory filing. The sale, conducted on March 4, 2025, was valued at approximately $107,407, with the shares sold at an average price of $10.29 each. The transaction comes as the stock, currently trading at $12.09, has shown significant volatility, gaining nearly 119% over the past six months according to InvestingPro data. The transaction was carried out to cover estimated withholding taxes upon the vesting of restricted share units, as per the automatic sale instructions outlined in the relevant agreement. With a market capitalization of $650 million, uniQure maintains strong liquidity, as InvestingPro analysis shows the company’s current ratio at 9.74, indicating robust short-term financial health.
In addition to the sale, Klemt acquired 73,000 restricted share units on March 3, 2025, under the company’s 2014 Share Incentive Plan, which vest in equal annual installments over three years. He also received stock options for 126,000 ordinary shares, exercisable at $10.90 per share, with vesting conditions tied to his continued tenure at the company. Following these transactions, Klemt holds 217,730 shares directly.
These transactions reflect Klemt’s ongoing participation in uniQure’s equity incentive programs and his role in managing tax obligations associated with equity awards.
In other recent news, uniQure has announced the pricing of its public offering, setting the share price at $17 with the aim of raising approximately $75 million. The offering is expected to close around January 10, 2025, subject to customary conditions, and includes a provision for underwriters to purchase additional shares. Meanwhile, H.C. Wainwright has reaffirmed its Buy rating for uniQure, raising the price target to $70, highlighting optimism about the company’s gene therapy pipeline, particularly the AMT-130 program for Huntington’s disease. The firm emphasized upcoming regulatory updates that could significantly impact the company’s valuation.
In other developments, uniQure has completed enrollment for the first cohort of its Phase I/IIa trial of AMT-191, a gene therapy for Fabry disease, with no significant safety concerns reported. The U.S. Food and Drug Administration has granted the therapy Orphan Drug status and Fast Track designation. Additionally, CSL (OTC:CSLLY) Behring, which licensed the global rights to commercialize HEMGENIX from uniQure, confirmed the long-term efficacy of the hemophilia B treatment in a four-year study. The study demonstrated sustained factor IX activity levels and a significant reduction in bleeding rates, with no serious adverse events reported.
These recent developments underscore uniQure’s active role in advancing gene therapy treatments for various conditions. The company’s ongoing trials and collaborations reflect its strategic focus on addressing unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.